Trial summary
This is a secondary data use non-interventional study of patients in Australia who received Sacituzumab govitecan (Trodelvy), for the treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Receptor status / problem studied
Cake ice cream fruitcake lollipop jelly beans chocolate cake soufflé. Cake soufflé halvah pudding fruitcake gummies sugar plum. Pudding croissant cotton candy icing marshmallow dessert. Bear claw soufflé marzipan topping bonbon.
Trial details
Trial title
TRACIE
Diagnosis
Condition 3
Type of treatment
Haematology
Phase
Phase 3
Locations